Analgesic Effectiveness of Three Different Doses of a New Formulation of Lamaline in a Model of Painful Knee (Gonarthrosis)
Phase 3
Completed
- Conditions
- Knee Osteoarthritis
- Registration Number
- NCT00264225
- Lead Sponsor
- Solvay Pharmaceuticals
- Brief Summary
This study aims to assess the analgesic effectiveness and safety of three different doses of a new formulation of Lamaline® versus Dafalgan® Codeine after 10 days administration in subjects with painful gonarthrosis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- History of knee (unilateral or bilateral) osteoarthritis for at least 6 months
- Pain intensity assessed by Visual Analogue Scale ≥ 40 mm
- Partial functional disability assessed by Lequesne index ≥4 and < than 12
Exclusion Criteria
- Patient unable to interrupt his/her NSAIDs to participate in the clinical study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (171)
Site 2
🇫🇷Albi, France
Site 3
🇫🇷Andernos Les Bains, France
Site 101
🇫🇷Angers, France
Site 103
🇫🇷Angers, France
Site 105
🇫🇷Angers, France
Site 106
🇫🇷Angers, France
Site 107
🇫🇷Angers, France
Site 108
🇫🇷Angers, France
Site 109
🇫🇷Angers, France
Site 110
🇫🇷Angers, France
Scroll for more (161 remaining)Site 2🇫🇷Albi, France